<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" >

<channel>
	<title>Pill Pals</title>
	<atom:link href="https://pillpals.co/feed/" rel="self" type="application/rss+xml" />
	<link>https://pillpals.co</link>
	<description>Licensed pharmacy service helping patients save on common medications.</description>
	<lastBuildDate>Sat, 25 Jul 2026 07:45:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>
	<itunes:subtitle>Pill Pals</itunes:subtitle>
	<itunes:summary>Licensed pharmacy service helping patients save on common medications.</itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<item>
		<title>Percutaneous Catheter Issue from Boston Scientific</title>
		<link>https://pillpals.co/percutaneous-catheter-issue-from-boston-scientific/</link>
					<comments>https://pillpals.co/percutaneous-catheter-issue-from-boston-scientific/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Sat, 25 Jul 2026 07:45:27 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/percutaneous-catheter-issue-from-boston-scientific/</guid>

					<description><![CDATA[CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product ENROUTE NPS ENROUTE NPS Plus The FDA is aware that Boston Scientific has issued a letter to affected customers [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/percutaneous-catheter-issue-from-boston-scientific/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer</title>
		<link>https://pillpals.co/fda-approves-zidesamtinib-for-ros1-positive-non-small-cell-lung-cancer/</link>
					<comments>https://pillpals.co/fda-approves-zidesamtinib-for-ros1-positive-non-small-cell-lung-cancer/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Sat, 25 Jul 2026 06:45:18 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/fda-approves-zidesamtinib-for-ros1-positive-non-small-cell-lung-cancer/</guid>

					<description><![CDATA[On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI). Full prescribing information for Jideytro will be posted on Drugs@FDA Efficacy was evaluated in ARROS-1 (NCT05118789), a [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/fda-approves-zidesamtinib-for-ros1-positive-non-small-cell-lung-cancer/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG</title>
		<link>https://pillpals.co/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-2g-100ml-20mg/</link>
					<comments>https://pillpals.co/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-2g-100ml-20mg/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Sat, 25 Jul 2026 06:45:11 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-2g-100ml-20mg/</guid>

					<description><![CDATA[Summary Company Announcement Date: July 24, 2026 FDA Publish Date: July 24, 2026 Product Type: Drugs Reason for Announcement: Recall Reason Description Particulate matter (cardboard) found in the solution. Company Name: Baxter International Inc. Brand Name: Product Description: Product Description Cefazolin in Dextrose Injection Company Announcement July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-2g-100ml-20mg/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Advancing Novel Surrogate Endpoints For Rare Disease Drug Development</title>
		<link>https://pillpals.co/advancing-novel-surrogate-endpoints-for-rare-disease-drug-development/</link>
					<comments>https://pillpals.co/advancing-novel-surrogate-endpoints-for-rare-disease-drug-development/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 19:46:33 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/advancing-novel-surrogate-endpoints-for-rare-disease-drug-development/</guid>

					<description><![CDATA[Date: May 18, 2026 Time: 9:00 a.m. &#8211; 4:30 p.m. ET Register Here To facilitate rare disease drug development, and as part of a performance goal and requirement related to the FDA User Fee Reauthorization Act of 2022 and the Food and Drug Omnibus Reform Act of 2022 (FDORA), respectively, the U.S. Food and Drug [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/advancing-novel-surrogate-endpoints-for-rare-disease-drug-development/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>OTP INTERACT Meetings</title>
		<link>https://pillpals.co/otp-interact-meetings/</link>
					<comments>https://pillpals.co/otp-interact-meetings/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 18:50:19 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/otp-interact-meetings/</guid>

					<description><![CDATA[Prior to the INTERACT Meeting For INTERACT Meetings, as indicated in the table above, OTP will send the preliminary response no later than 5 days before the scheduled meeting.  The sponsor is expected to respond to OTP’s preliminary responses not later than 3 days prior to the scheduled teleconference (see Table above). If the sponsor [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/otp-interact-meetings/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>FDA Approves Combination of Acetaminophen and Naproxen Sodium</title>
		<link>https://pillpals.co/fda-approves-combination-of-acetaminophen-and-naproxen-sodium/</link>
					<comments>https://pillpals.co/fda-approves-combination-of-acetaminophen-and-naproxen-sodium/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 18:50:15 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/fda-approves-combination-of-acetaminophen-and-naproxen-sodium/</guid>

					<description><![CDATA[On July 24, FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets), the first fixed-dose combination product to pair acetaminophen with naproxen sodium in a single combination tablet for up to 12 hours of pain relief. This nonprescription product is indicated for the temporary relief of minor aches and pains due to [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/fda-approves-combination-of-acetaminophen-and-naproxen-sodium/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Southern Tick–Associated Rash Illness in Pediatric Patient, New York, USA, 2025</title>
		<link>https://pillpals.co/southern-tick-associated-rash-illness-in-pediatric-patient-new-york-usa-2025/</link>
					<comments>https://pillpals.co/southern-tick-associated-rash-illness-in-pediatric-patient-new-york-usa-2025/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 18:50:10 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/southern-tick-associated-rash-illness-in-pediatric-patient-new-york-usa-2025/</guid>

					<description><![CDATA[Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA (A.S. Handel); Stony Brook University, Stony Brook (S. Ahmed, I. Rochlin, H.K. Kim) Southern [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/southern-tick-associated-rash-illness-in-pediatric-patient-new-york-usa-2025/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>BK261351- ADAMII CD34 System</title>
		<link>https://pillpals.co/bk261351-adamii-cd34-system/</link>
					<comments>https://pillpals.co/bk261351-adamii-cd34-system/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 17:55:22 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/bk261351-adamii-cd34-system/</guid>

					<description><![CDATA[510(k) Number: BK261351Applicant: NanoEntek, IncDevice Name: ADAMII CD34 SystemDecision Date: 07/20/2026 Supporting Documents Content current as of: 07/24/2026 Source]]></description>
		
					<wfw:commentRss>https://pillpals.co/bk261351-adamii-cd34-system/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter</title>
		<link>https://pillpals.co/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-of-cyclophosphamide-for-injection-usp-to-the-user-level-due-to-the-presence-of-particulate-matter/</link>
					<comments>https://pillpals.co/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-of-cyclophosphamide-for-injection-usp-to-the-user-level-due-to-the-presence-of-particulate-matter/#respond</comments>
		
		<dc:creator><![CDATA[Pill Pals Pharmacy Team]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 17:55:17 +0000</pubDate>
				<category><![CDATA[News From Around The Web]]></category>
		<guid isPermaLink="false">https://pillpals.co/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-of-cyclophosphamide-for-injection-usp-to-the-user-level-due-to-the-presence-of-particulate-matter/</guid>

					<description><![CDATA[Summary Company Announcement Date: July 24, 2026 FDA Publish Date: July 24, 2026 Product Type: Drugs Reason for Announcement: Recall Reason Description Presence of particulate matter identified as steel Company Name: Sunny Pharmtech, Inc. Brand Name: Brand Name(s) Long Grove Pharmaceuticals Product Description: Product Description Cyclophosphamide for Injection Company Announcement July 24, 2026 &#8211; Taoyuan [&#8230;]]]></description>
		
					<wfw:commentRss>https://pillpals.co/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-of-cyclophosphamide-for-injection-usp-to-the-user-level-due-to-the-presence-of-particulate-matter/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
